Proof of principle for epitope-focused vaccine design
Open accessThe DOI matches its Crossref record; 37 of the 38 references it cites were found in a registry or an index.
Abstract
Vaccines prevent infectious disease largely by inducing protective neutralizing antibodies against vulnerable epitopes. Several major pathogens have resisted traditional vaccine development, although vulnerable epitopes targeted by neutralizing antibodies have been identified for several such cases. Hence, new vaccine design methods to induce epitope-specific neutralizing antibodies are needed. Here we show, with a neutralization epitope from respiratory syncytial virus, that computational protein design can generate small, thermally and conformationally stable protein scaffolds that accurately mimic the viral epitope structure and induce potent neutralizing antibodies. These scaffolds represent promising leads for the research and development of a human respiratory syncytial virus vaccine needed to protect infants, young children and the elderly. More generally, the results provide proof of principle for epitope-focused and scaffold-based vaccine design, and encourage the evaluation and further development of these strategies for a variety of other vaccine targets, including antigenically highly variable pathogens such as human immunodeficiency virus and influenza.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures














Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Previous methods can scaffold functional sites made up of one or two contiguous chain segments (6–10), but with the exception of helical bundles (8) these do not extend readily to more complex sites composed of three or more chain segments, and the generated backbones are not guaranteed to be designable (encodable by some amino acid sequence).”
From Scaffolding protein functional sites using deep learning (2022) · cites this paper as [7]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Previous methods can scaffold functional sites made up of one or two contiguous chain segments (6–10), but with the exception of helical bundles (8) these do not extend readily to more complex sites composed of three or more chain segments, and the generated backbones are not guaranteed to be designable (encodable by some amino acid sequence).”
From Scaffolding protein functional sites using deep learning (2022) · cites this paper as [7]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Previous methods can scaffold functional sites made up of one or two contiguous chain segments (6–10), but with the exception of helical bundles (8) these do not extend readily to more complex sites composed of three or more chain segments, and the generated backbones are not guaranteed to be designable (encodable by some amino acid sequence).”
From Scaffolding protein functional sites using deep learning (2022) · cites this paper as [7]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
NMRPipe: A multidimensional spectral processing system based on UNIX pipes
Delaglio, F., Grzesiek, S., Vuister, G., Zhu, G., Pfeifer, J., & Bax, A. (1995) · Journal of Biomolecular NMR · doi:10.1007/bf00197809 · Cited by 15,965
Lozano, R., Naghavi, M., Foreman, K., Lim, S., Shibuya, K., Aboyans, V., Abraham, J., Adair, T., Aggarwal, R., Ahn, S. Y., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)61728-0 · Cited by 14,070
The global distribution and burden of dengue
Bhatt, S., Gething, P. W., Brady, O. J., Messina, J. P., Farlow, A. W., Moyes, C. L., Drake, J. M., Brownstein, J. S., Hoen, A. G., Sankoh, O., et al. (2013) · Nature · doi:10.1038/nature12060 · Cited by 10,037
Murray, C. J. L., Vos, T., Lozano, R., Naghavi, M., Flaxman, A. D., Michaud, C., Ezzati, M., Shibuya, K., Salomon, J. A., Abdalla, S., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)61689-4 · Cited by 8,888
NMR View: A computer program for the visualization and analysis of NMR data
Johnson, B. A., & Blevins, R. A. (1994) · Journal of Biomolecular NMR · doi:10.1007/bf00404272 · Cited by 3,090
Vaccination with ALVAC and AIDSVAX to Prevent HIV-1 Infection in Thailand
Rerks-Ngarm, S., Pitisuttithum, P., Nitayaphan, S., Kaewkungwal, J., Chiu, J., Paris, R., Premsri, N., Namwat, C., de Souza, M., Adams, E., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0908492 · Cited by 3,034
Leaver-Fay (2011) · doi:10.1016/b978-0-12-381270-4.00019-6 · Cited by 1,904
Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis
Osterholm, M. T., Kelley, N. S., Sommer, A., & Belongia, E. A. (2012) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(11)70295-x · Cited by 1,789
Protein Structure Prediction Using Rosetta
Rohl, C. A., Strauss, C. E. M., Misura, K. M. S., & Baker, D. (2004) · Methods in Enzymology · doi:10.1016/s0076-6879(04)83004-0 · Cited by 1,725
Self-citationDesign of a Novel Globular Protein Fold with Atomic-Level Accuracy
Kuhlman, B., Dantas, G., Ireton, G. C., Varani, G., Stoddard, B. L., & Baker, D. (2003) · Science · doi:10.1126/science.1089427 · Cited by 1,670
Self-citation
Research works printed but not linked: 1
- Plotkin SA Orenstein WA Offit PA Vaccines 6 Elsevier 2012
Cited by
Items 201–300 of 554
Affinity selection of epitope-based vaccines using a bacteriophage virus-like particle platform
O’Rourke, J. P., Peabody, D. S., & Chackerian, B. (2015) · Current Opinion in Virology · doi:10.1016/j.coviro.2015.03.005 · Cited by 32
Ghodake, G. S., Shinde, S. K., Kadam, A. A., Saratale, R. G., Saratale, G. D., Syed, A., Elgorban, A. M., Marraiki, N., & Kim, D.-Y. (2021) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2021.112969 · Cited by 34
Thornlow, D. N., Macintyre, A. N., Oguin, T. H., Karlsson, A., Stover, E. L., Lynch, H. E., Sempowski, G. D., & Schmidt, A. G. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.737973 · Cited by 30
“Current immunogendesign efforts for next generation influenza vaccines are focused on eliciting protective antibodies targeting these conserved epitopes (32).”
BackgroundStanfield, R. L., Castro, C. D., Marzaioli, A. M., Wilson, I. A., & Pantophlet, R. A. (2014) · Glycobiology · doi:10.1093/glycob/cwu123 · Cited by 31
Integrating gene synthesis and microfluidic protein analysis for rapid protein engineering
Blackburn, M., Petrova, E., Correia, B. E., & Maerkl, S. J. (2015) · Nucleic Acids Research · doi:10.1093/nar/gkv1497 · Cited by 28
“Nonetheless, computational approaches are becoming adept at informing protein design and predicting function (2,3), and techniques that permit the rapid generation and quantitative characterization of designed protein variants would greatly aid protein engineering and further improve the accuracy of computational appr…”
Self-citationStructure-based immunogen design — leading the way to the new age of precision vaccines
Sesterhenn, F., Bonet, J., & Correia, B. E. (2018) · Current Opinion in Structural Biology · doi:10.1016/j.sbi.2018.06.002 · Cited by 29
Self-citationTracing Antibody Repertoire Evolution by Systems Phylogeny
Yermanos, A., Dounas, A., Stadler, T., Oxenius, A., & Reddy, S. T. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02149 · Cited by 30
“Further work has attempted to design vaccine immunogens that target these intermediate progenitor sequences in hopes of directing the subsequent evolution of antibodies toward the broadly neutralizing phenotype (40, 41).”
BackgroundIvanochko, D., Fabra-García, A., Teelen, K., van de Vegte‐Bolmer, M., van Gemert, G., Newton, J. C., Semesi, A., de Bruijni, M. H. C., Bolscher, J. M., Ramjith, J., et al. (2023) · Immunity · doi:10.1016/j.immuni.2023.01.013 · Cited by 29
Prediction of Misfolding-Specific Epitopes in SOD1 Using Collective Coordinates
Peng, X., Cashman, N. R., & Plotkin, S. S. (2018) · The Journal of Physical Chemistry B · doi:10.1021/acs.jpcb.8b07680 · Cited by 32
Zhang, L., Wang, J., Xu, A., Zhong, C., Lu, W., Deng, L., & Li, R. (2016) · PLoS ONE · doi:10.1371/journal.pone.0163080 · Cited by 31
Jaberolansar, N., Chappell, K. J., Watterson, D., Bermingham, I. M., Tóth, I., Young, P. R., & Skwarczyński, M. (2017) · Scientific Reports · doi:10.1038/s41598-017-10415-w · Cited by 30
Raza, S., Siddique, K., Rabbani, M., Yaqub, T., Anjum, A. A., Ibrahim, M. K., Azhar, M., Jamil, F., & Rasheed, M. A. (2019) · Microbial Pathogenesis · doi:10.1016/j.micpath.2019.01.007 · Cited by 29
Anti-idiotypic antibodies elicit anti-HIV-1–specific B cell responses
Dosenovic, P., Pettersson, A.-K., Wall, A., Thientosapol, E. S., Feng, J., Weidle, C., Bhullar, K., Kara, E. E., Hartweger, H., Pai, J. A., et al. (2019) · The Journal of Experimental Medicine · doi:10.1084/jem.20190446 · Cited by 30
“Examples include the development of scaffolds that carry the conserved epitopes (Ofek et al., 2010; Azoitei et al., 2011; Correia et al., 2014; Zhou et al., 2014), the use of short linear peptides that encompass target epitopes (Wang et al., 2010; Alam et al., 2017; Xu et al., 2018), shielding or…”
BackgroundJoh, N. H., Grigoryan, G., Wu, Y., & DeGrado, W. F. (2017) · Philosophical Transactions of the Royal Society B Biological Sciences · doi:10.1098/rstb.2016.0214 · Cited by 30
Aebischer, A., Wernike, K., König, P., Franzke, K., Schreur, P. J. W., Kortekaas, J., Vitikainen, M., Wiebe, M. G., Saloheimo, M., Tchelet, R., et al. (2021) · Vaccines · doi:10.3390/vaccines9060651 · Cited by 27
“However, de novo designed epitope-based vaccines seldomly induce appropriate humoral immune responses, since the epitopes are generally not presented in their native conformation [51,52].”
BackgroundProbing the Impact of Local Structural Dynamics of Conformational Epitopes on Antibody Recognition
Liang, Y., Guttman, M., Davenport, T. M., Hu, S.-L., & Lee, K. K. (2016) · Biochemistry · doi:10.1021/acs.biochem.5b01354 · Cited by 26
Liang, Y., Guttman, M., Williams, J. A., Verkerke, H., Alvarado, D., Hu, S.-L., & Lee, K. K. (2016) · Journal of Virology · doi:10.1128/jvi.01116-16 · Cited by 31
Morris, C. D., Azadnia, P., de Val, N., Vora, N., Honda, A., Giang, E., Saye-Francisco, K. L., Cheng, Y., Lin, X., Mann, C. J., et al. (2017) · mBio · doi:10.1128/mbio.00036-17 · Cited by 28
Nanovaccines for Advancing Long-Lasting Immunity against Infectious Diseases
Gao, X., Wang, X., Li, S., Rahman, M. S. U., Xu, S., & Liu, Y. (2023) · ACS Nano · doi:10.1021/acsnano.3c07741 · Cited by 29
Immunogen design for HIV-1 and influenza
Rathore, U., Kesavardhana, S., Mallajosyula, V. V. A., & Varadarajan, R. (2014) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2014.05.010 · Cited by 29
The Hard Way towards an Antibody-Based HIV-1 Env Vaccine: Lessons from Other Viruses
Ringel, O., Vieillard, V., Debré, P., Eichler, J., Büning, H., & Dietrich, U. (2018) · Viruses · doi:10.3390/v10040197 · Cited by 33
“This approach of structure-based reverse vaccinology or epitope-focused vaccine design is conceptually very elegant and has recently been proven to work in terms of inducing epitope-specific neutralizing antibodies against the respiratory syncytial virus (RSV) in vaccinated macaques, when the epitope was presented on…”
BackgroundDingens, A. S., Pratap, P. P., Malone, K. D., Hilton, S. K., Ketas, T. J., Cottrell, C. A., Overbaugh, J. M., Moore, J. P., Klasse, P. J., Ward, A. B., et al. (2021) · eLife · doi:10.7554/elife.64281 · Cited by 32
In silico Designing of an Epitope-Based Vaccine Against Common E. coli Pathotypes
Soltan, M. A., Behairy, M. Y., Abdelkader, M. S., Albogami, S. M., Fayad, E., Eid, R. A., Darwish, K. M., Elhady, S. S., Lotfy, A., & Eldeen, M. A. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.829467 · Cited by 29
“Vaccine construction using mapped epitopes is a sophisticated strategy to trigger an immune response against infectious agents (88).”
BackgroundEngineered immunogens to elicit antibodies against conserved coronavirus epitopes
(2023) · doi:10.1038/s41467-023-43638-9 · Cited by 26
“…epitope scaffolds de novo by folding idealized protein backbones around the target epitope, as was previously done for epitopes on RSV 18,29 , or by modifying the backbone of existing proteins to adopt the conformation of the grafted epitope, as illustrated before for HIV 26,27 and here…”
Rationally designed carbohydrate-occluded epitopes elicit HIV-1 Env-specific antibodies
Zhu, C., Dukhovlinova, E., Ping, L., Faison, E. M., Prabhu, S. S., Potter, E. L., Upton, S. L., Yin, G., Fay, J. M., Kincer, L. P., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-08876-w · Cited by 28
Moving from Empirical to Rational Vaccine Design in the ‘Omics’ Era
Sharma, M., Krammer, F., García‐Sastre, A., & Tripathi, S. (2019) · Vaccines · doi:10.3390/vaccines7030089 · Cited by 29
Structure-Guided Molecular Grafting of a Complex Broadly Neutralizing Viral Epitope
Bajic, G., Maron, M. J., Caradonna, T. M., Tian, M., Mermelstein, A. G., Fera, D., Kelsoe, G. H., Kuraoka, M., & Schmidt, A. G. (2020) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.0c00008 · Cited by 27
Apellániz, B., & Nieva, J. L. (2015) · Advances in protein chemistry and structural biology · doi:10.1016/bs.apcsb.2015.03.002 · Cited by 26
Lay, M. K., Bueno, S. M., Gálvez, N. M. S., Riedel, C. A., & Kalergis, A. M. (2015) · Critical Reviews in Microbiology · doi:10.3109/1040841x.2015.1055711 · Cited by 31
“While vaccines against RSV are not commercially available yet, significant research efforts are currently in progress to obtain a safe and effective formulation that prevents the disease caused by this virus (Bueno et al., 2008a; Correia et al., 2014; Liang et al., 2014; McLellan et al., 2013).”
BackgroundIndelicato, G., Burkhard, P., & Twarock, R. (2017) · Royal Society Open Science · doi:10.1098/rsos.161092 · Cited by 25
“To generate an optimal humoral immune resp onse, repetitive antigen display is a key determinant [24, 25, 26, 27, 28, 29, 30, 31, 32].”
BackgroundEngineered Repeat Protein Hybrids: The New Horizon for Biologic Medicines and Diagnostic Tools
Uribe, K. B., Guisasola, E., Aires, A., López‐Martínez, E., Guedes, G., Sasselli, I. R., & Cortajarena, A. L. (2021) · Accounts of Chemical Research · doi:10.1021/acs.accounts.1c00440 · Cited by 26
Alternative medications in shrimp health management for improved production
Citarasu, T., Babu, M. M., & Yılmaz, E. (2022) · Aquaculture · doi:10.1016/j.aquaculture.2022.738695 · Cited by 32
Cappelli, L., Cinelli, P., Giusti, F., Ferlenghi, I., Lanfaloni, S. U., Wahome, N., Bottomley, M. J., Maione, D., & Cozzi, R. (2022) · PLoS ONE · doi:10.1371/journal.pone.0273322 · Cited by 25
“Immuno-focusing by displaying multiple copies of a key epitope on a nanoparticle was previously demonstrated [85].”
George, M. T., Schloegel, J., Ntumngia, F. B., Barnes, S. J., King, C. L., Casey, J. L., Foley, M., & Adams, J. H. (2019) · mSphere · doi:10.1128/msphere.00194-19 · Cited by 26
Zhu, R., Liu, J., Chen, C.-Y., Ye, X., Xu, L., Wang, W. J., Zhao, Q., Zhu, H., Cheng, T., & Xia, N. (2016) · Vaccine · doi:10.1016/j.vaccine.2016.02.007 · Cited by 26
Type VI secretion system sheaths as nanoparticles for antigen display
Tordello, E. D., Danilchanka, O., McCluskey, A. J., & Mekalanos, J. J. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1524290113 · Cited by 24
Sabban, S., & Markovsky, M. (2020) · F1000Research · doi:10.12688/f1000research.22907.1 · Cited by 44
Subdominance in Antibody Responses: Implications for Vaccine Development
Lindahl, G. (2020) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.00078-20 · Cited by 25
“A protein region that is not immunodominant is now commonly referred to as subdominant, but the terms nonimmunodominant (17, 30–32), immunosubdominant (33), cryptic (34), and immunorecessive (35, 36) have also been used.”
BackgroundEpitope-specific immunity against Staphylococcus aureus coproporphyrinogen III oxidase
Klimka, A., Mertins, S., Nicolai, A. K., Rummler, L. M., Higgins, P. G., Günther, S. D., Tosetti, B., Krut, O., & Krönke, M. (2021) · npj Vaccines · doi:10.1038/s41541-020-00268-2 · Cited by 26
Durie, I. A., Tehrani, Z. R., Karaaslan, E., Sorvillo, T. E., McGuire, J. R., Golden, J. W., Welch, S. R., Kainulainen, M. H., Harmon, J. R., Mousa, J. J., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-34923-0 · Cited by 27
Computational Protein Design for COVID-19 Research and Emerging Therapeutics
Kalita, P., Tripathi, T., & Padhi, A. K. (2023) · ACS Central Science · doi:10.1021/acscentsci.2c01513 · Cited by 27
A Novel Neutralizing Antibody Specific to the DE Loop of VP1 Can Inhibit EV-D68 Infection in Mice
Zheng, H., Wang, J., Li, B., Guo, L., Li, H., Song, J., Yang, Z., Li, H., Fan, H., Huang, X., et al. (2018) · The Journal of Immunology · doi:10.4049/jimmunol.1800655 · Cited by 26
“TheAb/virus interaction at structural regions such as the DE loop might be regarded as a key to designing an efficient EV-D68 vaccine through genetic engineering via reverse vaccinology (53, 54).”
BackgroundAntibody Responses in Hepatitis C Infection
Law, M. (2020) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a036962 · Cited by 30
“…strategy focuses not only on designing vaccine antigens to better present the broadly neutralizing epitopes to the immune system (i.e., the epitope-based approach) (Correia et al. 2014), but also on guiding the affinity maturation process of naive, precursor B cells to produce bnAbs.”
BackgroundMapping and modeling of a strain-specific epitope in the Norwalk virus capsid inner shell
Parra, G. I., Sosnovtsev, S. V., Abente, E. J., Sandoval-Jaime, C., Bok, K., Dolan, M. A., & Green, K. Y. (2016) · Virology · doi:10.1016/j.virol.2016.02.019 · Cited by 24
The Case for Exploiting Cross-Species Epitopes in Malaria Vaccine Design
Mitran, C. J., & Yanow, S. K. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00335 · Cited by 27
Wec, A. Z., Wrapp, D., Herbert, A. S., Maurer, D. P., Haslwanter, D., Sakharkar, M., Jangra, R. K., Dieterle, M. E., Lilov, A., Huang, D., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.05.15.096511 · Cited by 23
“For example, the RBD epitope(s) defined by this class of antibodies could be presented on conformationally stable protein scaffolds to focus the antibody response on this site, as previously demonstrated for the motavizumab epitope on RSV F(31).”
BackgroundSelf-citationWidman, D. G., Young, E., Nivarthi, U. K., Swanstrom, J., Royal, S. R., Yount, B. L., Debbink, K. M., Begley, M., Marcet, S., Durbin, A. P., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-17355-5 · Cited by 22
Discovering genomic patterns in SARS‐CoV‐2 variants
D’Angelo, G., & Palmieri, F. (2020) · International Journal of Intelligent Systems · doi:10.1002/int.22268 · Cited by 22
Structural vaccinology of malaria transmission-blocking vaccines
Patel, P. N., & Tolia, N. H. (2021) · Expert Review of Vaccines · doi:10.1080/14760584.2021.1873135 · Cited by 24
Computational design of vaccine immunogens
Castro, K. M., Scheck, A., Xiao, S., & Correia, B. E. (2022) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2022.102821 · Cited by 25
Self-citationEpitope-imprinted biomaterials with tailor-made molecular targeting for biomedical applications
Diao, Y., Gao, J. C., Ma, Y., & Pan, G. (2024) · Bioactive Materials · doi:10.1016/j.bioactmat.2024.11.012 · Cited by 37
Wu, M., Li, M., Yue, Y., & Xu, W. (2016) · Microbiology and Immunology · doi:10.1111/1348-0421.12410 · Cited by 22
Immunization Against Viral Diseases
Ledgerwood, J. E., & Graham, B. S. (2016) · ASM Press eBooks · doi:10.1128/9781555819439.ch17 · Cited by 22
Self-citationReprogramming cellular functions with engineered membrane proteins
Arber, C., Young, M., & Barth, P. (2017) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2017.06.009 · Cited by 21
“By contrast to soluble proteins [46], the scarcity of membrane receptor structures has prevented the broad application of computational design techniques to membrane proteins.”
Liguori, A., Iacono, L. D., Maruggi, G., Benucci, B., Merola, M., Surdo, P. L., López‐Sagaseta, J., Pizza, M., Malito, E., & Bottomley, M. J. (2018) · mBio · doi:10.1128/mbio.01914-18 · Cited by 21
“plored for a respiratory syncytial virus vaccine (42).”
BackgroundWang, J., Zhang, J., Sun, X., Liu, C., Li, X., & Chen, L. (2019) · Chemical Biology & Drug Design · doi:10.1111/cbdd.13501 · Cited by 22
Azoitei, M. L., Ban, Y. A., Kalyuzhny, O., Guenaga, J., Schroeter, A., Porter, J. R., Wyatt, R. T., & Schief, W. R. (2014) · Proteins Structure Function and Bioinformatics · doi:10.1002/prot.24641 · Cited by 23
Self-citationLi, Y., Abdul‐Rashid, S. H., & Ghazilla, R. A. R. (2022) · Sustainability · doi:10.3390/su14052545 · Cited by 23
Self-citationWang, R., Suzuki, S., Guest, J. D., Heller, B. L., Almeda, M., Andrianov, A. K., Marin, A., Mariuzza, R. A., Keck, Z., Foung, S. K. H., et al. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2112008119 · Cited by 21
Flu Universal Vaccines: New Tricks on an Old Virus
Du, R., Cui, Q., & Rong, L. (2020) · Virologica Sinica · doi:10.1007/s12250-020-00283-6 · Cited by 27
“Monoclonal antibodies against this domain can broadly neutralize different subtypes of group 1 (Okuno et al. 1993; Ekiert et al. 2009; Sui et al. 2009) or group 2 viruses (Ekiert et al. 2011) or even both (Corti et al. 2011).”
BackgroundBozhanova, N. G., Sangha, A. K., Sevy, A. M., Gilchuk, P., Huang, K., Nargi, R. S., Reidy, J. X., Trivette, A., Carnahan, R. H., Bukreyev, A. A., et al. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1922654117 · Cited by 22
“Ultimately, such Ab repertoires may provide or add templates for developing epitope-focused (1) and germline-targeting (2, 3) vaccines.”
BackgroundSelf-citationAn epitope-specific chemically defined nanoparticle vaccine for respiratory syncytial virus
Zúñiga, A., Rassek, O., Vrohlings, M., Marrero, A., Moehle, K., Robinson, J. A., & Ghasparian, A. (2021) · npj Vaccines · doi:10.1038/s41541-021-00347-y · Cited by 21
Antibodies: Computer-Aided Prediction of Structure and Design of Function
Sevy, A. M., & Meiler, J. (2014) · Microbiology Spectrum · doi:10.1128/microbiolspec.aid-0024-2014 · Cited by 23
“Recently, an important proof-of-principle experiment for computer-aided epitope-focused vaccine design was reported (42).”
BackgroundMethodInfluentialA generic framework for hierarchical de novo protein design
Harteveld, Z., Bonet, J., Rosset, S., Yang, C., Sesterhenn, F., & Correia, B. E. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2206111119 · Cited by 21
“We use the previously developed Rosetta FunFolDes (FFD) [45], [46] protocol to generate an initial set of poly-valine backbone conformations using Cα-based distance restraints calculated between all different SSEs and perform sequence design.”
MethodSelf-citationEpitope-focused immunogen design based on the ebolavirus glycoprotein HR2-MPER region
Schoeder, C. T., Gilchuk, P., Sangha, A. K., Ledwitch, K. V., Malherbe, D. C., Zhang, X., Binshtein, E., Williamson, L. E., Martina, C. E., Dong, J., et al. (2022) · PLoS Pathogens · doi:10.1371/journal.ppat.1010518 · Cited by 18
Self-citationStructure‐based computational design of antibody mimetics: challenges and perspectives
Chaves, E. J. F., Coêlho, D. F., da Cruz, C. H. B., Moreira, E. G., Simões, J., Nascimento‐Filho, M. J., & Lins, R. D. (2024) · FEBS Open Bio · doi:10.1002/2211-5463.13855 · Cited by 26
Vaccine Design for H5N1 Based on B- and T-cell Epitope Predictions
Tambunan, U. S. F., Sipahutar, F. R. P., Parikesit, A. A., & Kerami, D. (2016) · Bioinformatics and Biology Insights · doi:10.4137/bbi.s38378 · Cited by 20
Vakili, B., Nezafat, N., Hatam, G., Zare, B., Erfani, N., & Ghasemi, Y. (2017) · Computational Biology and Chemistry · doi:10.1016/j.compbiolchem.2017.12.008 · Cited by 20
Mapping conformational epitopes by NMR spectroscopy
Valente, A. P., & Rendeiro, M. M. (2021) · Current Opinion in Virology · doi:10.1016/j.coviro.2021.04.001 · Cited by 20
A Chimeric Pneumovirus Fusion Protein Carrying Neutralizing Epitopes of Both MPV and RSV
Wen, X., Pickens, J. A., Mousa, J. J., Leser, G. P., Lamb, R. A., Crowe, J. E., & Jardetzky, T. S. (2016) · PLoS ONE · doi:10.1371/journal.pone.0155917 · Cited by 21
Self-citationFannjiang, C., & Listgarten, J. (2023) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a041469 · Cited by 25
“…al. 2020) and enzymes (Russ et al. 2020; Hawkins-Hooker et al. 2021; Repecka et al. 2021; Madani et al. 2023) A second type of novelty is in the structure—for example, when building a scaffold to contain and support a functional site (Correia et al. 2014; Sesterhenn et al. 2020; Wang et al. 2022).”
BackgroundOsmolytes in vaccine production, flocculation and storage: a critical review
Hasan, T., Kumari, K., Devi, S. C., Handa, J., Rehman, M. T., Ansari, N. A., & Singh, L. R. (2018) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2018.1526585 · Cited by 20
“In addition, anti-idiotype vaccines, also known as antigen-mimicking antibodies, are developed based on the idea that antibodies can also be used as antigen to elicit an immune response.(38,39) These are also monoclonal antibodies (mAbs) directed against many tumor-associated antigens for the treatment of cancer.”
BackgroundInfluenza Virus–Specific Human Antibody Repertoire Studies
Crowe, J. E. (2019) · The Journal of Immunology · doi:10.4049/jimmunol.1801459 · Cited by 19
“Proof-of-principle has been established for this reverse vaccinology approach in previous studies of another respiratory pathogen, respiratory syncytial virus (44).”
ResultSelf-citationVelázquez‐Moctezuma, R., Galli, A., Law, M., Bukh, J., & Prentoe, J. C. (2018) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiy481 · Cited by 19
Multiple-Allele MHC Class II Epitope Engineering by a Molecular Dynamics-Based Evolution Protocol
Ochoa, R., Lunardelli, V. A. S., Rosa, D. S., Laio, A., & Cossio, P. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.862851 · Cited by 18
“Rosetta applications (38) have been used to design epitope scaffolds for neutralizing antibodies (39), and to reduce the immunogenicty of a target protein by searching for its potential epitopes and designing less immunogenic sequences (40).”
MethodDuan, L., Zhang, J., Chen, Z., Gou, Q., Xiong, Q., Yuan, Y., Jing, H., Zhu, J., Ni, L., Zheng, Y., et al. (2021) · Journal of Inflammation Research · doi:10.2147/jir.s325286 · Cited by 19
Current and Novel Approaches in Influenza Management
Kotey, E. N., Lukosaityte, D., Quaye, O., Ampofo, W., Awandare, G. A., & Iqbal, M. (2019) · Vaccines · doi:10.3390/vaccines7020053 · Cited by 20
Li, Q., Wubshet, A. K., Wang, Y., Heath, L. E., & Zhang, J. (2023) · Viruses · doi:10.3390/v15030797 · Cited by 17
Wang, H., Chen, X., Wang, D., Yao, C., Wang, Q., Xie, J., Shi, X., Xiang, Y., Liu, W., & Zhang, L. (2017) · Journal of Biological Chemistry · doi:10.1074/jbc.m117.816447 · Cited by 18
Doran, R. C., Tatsuno, G. P., O’Rourke, S. M., Yu, B., Alexander, D. L., Mesa, K. A., & Berman, P. W. (2018) · PLoS ONE · doi:10.1371/journal.pone.0196370 · Cited by 17
Siewert, L. K., Korotaev, A., Sedzicki, J., Fromm, K., Pinschewer, D. D., & Dehio, C. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2202059119 · Cited by 17
Gu, H., Li, T., Han, L., Zhu, P., Zhang, P., Zhang, S., Sun, S., Duan, Y., Xing, L., Zhao, Z., et al. (2015) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2015.1011993 · Cited by 19
“A broad range of strategies have promoted RSV vaccine development, including live-attenuated RSV, plasmid DNA(20), and scaffoldbased vaccines.(21) However, to date no licensed vaccine has been shown to provide efficacy as well as safe, long-term protection against RSV infection due to insufficient immunogenicity and v…”
BackgroundKrapchev, V., Rychłowska, M., Chmielewska, A., Zimmer, K., Patel, A. H., & Bieńkowska-Szewczyk, K. (2018) · Virology · doi:10.1016/j.virol.2018.03.026 · Cited by 17
Ling, Z., Yi, C., Sun, X., Yang, Z., & Sun, B. (2022) · Science China Life Sciences · doi:10.1007/s11427-022-2215-6 · Cited by 16
“…variants, sarbecoviruses or human CoVs were isolated from convalescent patients or vaccinees, which provides good clues that the idea of a broad spectrum or universal vaccine might be successful if a new vaccine design method is used to induce epitope-specific bNAbs (Correia et al., 2014).”
MethodZeng, H., Zhang, J., Song, X., Zeng, J., Yuan, Y., Chen, Z., Xu, L., Gou, Q., Yang, F., Zeng, N., et al. (2020) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiaa602 · Cited by 16
Hsieh, C., Ptak, C. P., Tseng, A., Suguiura, I. M. D. S., McDonough, S. P., Sritrakul, T., Li, T., Lin, Y., Gillilan, R. E., Oswald, R. E., et al. (2017) · eLife · doi:10.7554/elife.30051 · Cited by 19
“Because the estimated worldwide burden of leptospiro- sis is over 1 million severe cases and ~60,000 deaths per year, advances in recombinant leptospiral vaccines are desperately needed and are likely to benefit from a structure-based antigen design strategy (Picardeau, 2017; Costa et al., 2015).”
BackgroundStructural patterns of selection and diversity for Plasmodium vivax antigens DBP and AMA1
Guy, A. J., Irani, V., Richards, J. S., & Ramsland, P. A. (2018) · Malaria Journal · doi:10.1186/s12936-018-2324-3 · Cited by 16
Murin, C. D., Gilchuk, P., Crowe, J. E., & Ward, A. B. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2021.808047 · Cited by 15
Self-citationCurrent and future prophylactic vaccines for hepatitis C virus
Patel, A. H., Dunlop, J. I., Owsianka, A. M., & Cowton, V. M. (2015) · Vaccine Development and Therapy · doi:10.2147/vdt.s48437 · Cited by 16
“128,129 Such changes of the natural structure could improve stability and antigenicity: a key issue with protein vaccination methods.”
BackgroundMethodChimeric Pneumoviridae fusion proteins as immunogens to induce cross‐neutralizing antibody responses
Olmedillas, E., Cano, O., Martínez, I., Luque, D., Terrón, M. C., McLellan, J. S., Melero, J. A., & Más, V. (2017) · EMBO Molecular Medicine · doi:10.15252/emmm.201708078 · Cited by 15
“In another case, the site II scaffold induced hRSV-neutralizing antibodies in macaques, but not in mice, after repeated doses (Correia et al, 2014).”
BackgroundMa, J., Wei, Y., Zhang, L., Wang, X., Yao, D., Liu, D., Liu, W. Y., Yu, S., Yu, Y., Wu, Z., et al. (2018) · Journal of Medical Microbiology · doi:10.1099/jmm.0.000633 · Cited by 15
Рудометов, А. П., Chikaev, A. N., Борисовна, Р. Н., Антонец, Д., Lomzov, A. A., Kaplina, O. N., Ilyichev, A. A., & Карпенко, Л. И. (2019) · Vaccines · doi:10.3390/vaccines7030083 · Cited by 18
“Epitope scaffolds developed by rational design were able to elicit 4E10 and 2F5-like antibodies in laboratory animals [28,29].”
BackgroundHCV Glycoprotein Structure and Implications for B-Cell Vaccine Development
Stroh, L. J., & Krey, T. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21186781 · Cited by 15
“virus (RSV) [122] and Influenza [125] have stimulated similar studies also on HCV neutralization epitopes [126–128].”
BackgroundSynthesis of multivalent glycopeptide conjugates that mimic an HIV epitope
Bailey, J. K., Nguyen, D. N. P., Horiya, S., & Krauss, I. J. (2016) · Tetrahedron · doi:10.1016/j.tet.2016.07.062 · Cited by 16
A Pan-Pneumovirus vaccine based on immunodominant epitopes of the fusion protein
Huang, J., Miller, R. J., & Mousa, J. J. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.941865 · Cited by 14
“Based on computational protein design strategies, RSV F site II was presented on a scaffold fused with RSV N-based nanoparticles, which boosted subdominant neutralizing antibody responses targeting antigenic site II in mice (49, 50).”
BackgroundThe bright side of chemistry: Exploring synthetic peptide‐based anticancer vaccines
D’Aniello, A., Bene, A. D., Mottola, S., Mazzarella, V., Cutolo, R., Campagna, E., Maro, S. D., & Messere, A. (2024) · Journal of Peptide Science · doi:10.1002/psc.3596 · Cited by 15
“25 Additionally, peptides can be modified to enhance stability and immune response, enabling a rational design of the vaccine.”
BackgroundA new strategy for development of hepatitis E vaccine: Epitope-based vaccines
(2015) · Pathogen & Infectious Disease · doi:10.14800/pid.933 · Cited by 14
An Epitope‐Specific Respiratory Syncytial Virus Vaccine Based on an Antibody Scaffold
Luo, X., Liu, T., Wang, Y., Jia, H., Zhang, Y., Caballero, D., Du, J., Wang, R. E., Wang, D., Schultz, P. G., et al. (2015) · Angewandte Chemie International Edition · doi:10.1002/anie.201507928 · Cited by 14
Sabah, S. N., Gazi, M. A., Sthity, R. A., Husain, A. B., Quyyum, S. A., Rahman, M., & Islam, R. (2016) · Interdisciplinary Sciences Computational Life Sciences · doi:10.1007/s12539-016-0184-5 · Cited by 15
Breakthroughs in computational design methods open up new frontiers for de novo protein engineering
Meinen, B. A., & Bahl, C. D. (2021) · Protein Engineering Design and Selection · doi:10.1093/protein/gzab007 · Cited by 14
Metadata
- Authors
- Correia, B. E., Bates, J. T., Loomis, R. J., Baneyx, G., Carrico, C., Jardine, J. G., Rupert, P., Correnti, C., Kalyuzhniy, O., Vittal, V., Connell, M. J., Stevens, E., Schroeter, A., Chen, M., MacPherson, S., Serra, A. M., Adachi, Y., Holmes, M. A., Li, Y., Klevit, R. E., Graham, B. S., Wyatt, R. T., Baker, D., Strong, R. K., Crowe, J. E., Johnson, P. R., & Schief, W. R.
- Affiliations
- Scripps Research Institute (US)
- Vanderbilt University Medical Center (US)
- Children's Hospital of Philadelphia (US)
- University of Washington (US)
- Fred Hutch Cancer Center (US)
- National Institutes of Health (US)
- Corresponding author
- Schief, William R.
- ORCID
- Venue
- Nature
- Published
- 2014-02-05
- Volume
- 507
- Issue
- 7491
- Pages
- 201-206
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC4260937
- OpenAlex
- W2040299410
- Cited by
- 555
- References
- 38
- Citations by year
- 2026: 39 · 2025: 40 · 2024: 37 · 2023: 32 · 2022: 55 · 2021: 44 · 2020: 43 · 2019: 45 · 2018: 40 · 2017: 47 · 2016: 50 · 2015: 52 · 2014: 30
- FWCI
- 24.45
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- cc-by-nc
- www.springernature.com/gp/researchers/text-and-data-mining (tdm)
- www.springernature.com/gp/researchers/text-and-data-mining (vor)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion, cc-by-nc)
- PubMed Central (acceptedVersion, cc-by-nc)
- Funders
- Bill and Melinda Gates Foundation
- International AIDS Vaccine Initiative
- March of Dimes Foundation
- Children's Hospital of Philadelphia
- University of Washington
- National Institutes of Health
- Center for AIDS Research, University of Washington
- University of California, San Diego
- National Cancer Institute (T32CA080416)
- National Institute of General Medical Sciences (T32GM007270)
- National Institute of Allergy and Infectious Diseases (P30AI 36214, U54AI057141, U54 AI 005714, R01AI102766, UM1AI100663, R21AI088554, P01AI094419, P30AI036214, P30AI045008)
- Center for AIDS Research, University of California, San Diego
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › vaccines and immunoinformatics approaches
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Structure and Dynamics
- Keywords
- RSV vaccine, neutralizing antibodies, computational protein design, protein scaffolds, antigenic determinants, vaccine development
- MeSH terms
- Animals, Antibodies, Monoclonal, Antibodies, Viral, Epitopes, Antigens, Viral, Enzyme-Linked Immunosorbent Assay, Macaca mulatta, Male, Mice, Inbred BALB C, Models, Molecular, Neutralization Tests, Protein Conformation, Respiratory Syncytial Viruses, Drug Design, Crystallography, X-Ray, Amino Acid Motifs, Respiratory Syncytial Virus Vaccines, Mice, Protein Stability, Antibodies, Neutralizing
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.